Prostate specific antigen-monitored combination radiotherapy for patients with prostate cancer. I-125 implant followed by external-beam radiation

摘要: Background. Because results of retropubic I-125 implantation for prostate cancer have been poor, external beam radiation was added postimplant. Serum specific antigen (PSA) used to assess this approach combined irradiation. Methods. Two hundred and thirty-nine patients with clinical Stage T1 or T2 but surgically node-negative were treated. Results monitored by serial serum PSA evaluation. Positive findings a rising level defined recurrent disease. Results. With median follow-up 45 months (range, 24-120 months), the Kaplan-Meier projected disease free survival rate 74% at 5 years 66% 10 years. Overall 60-month minimum follow-up, 77% had 0.5 ng/ml less. This nadir is highly predictive long term survival, significantly better than pretreatment PSA, grade, T2. Conclusions. The PSA-monitored after combination irradiation appears comparable that radical prostatectomy perhaps superior external-beam radiation. effect achieved even though lower-than-usual doses from both sources administered. an implant followed produces high within and, lesser extent, in periprostatic tissue. Additive synergistic effects simultaneous may be responsible these results. Cancer 1995 ;75 :2383-91.